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Clinical PerspectiveWhat Is New?Early experience with transcatheter mitral valve replacement supports its feasibility, with a high rate of technically successful valve implantation in selected patients.Transcatheter mitral valve replacement shows excellent hemodynamic results with a low rate of residual mitral regurgitation and low transvalvular gradients.Procedure‐related complications and midterm mortality remain relatively high.What Are the Clinical Implications?Transcatheter mitral valve replacement has emerged as an alternative treatment option for patients with prohibitive or high surgical risk.Further iterations of transcatheter mitral valve replacement systems, a gradual increase in use of the transfemoral--transeptal approach, and improved patient selection will be essential for a widespread adoption of this technology as an alternative to conventional surgery.

Introduction {#jah34376-sec-0008}
============

Mitral regurgitation (MR) is the leading cause of heart valve disease in Western countries and affects ≈10% of people aged \>75 years.[1](#jah34376-bib-0001){ref-type="ref"} Conventional mitral valve surgery (either repair or replacement) remains the standard of care for patients with symptomatic severe MR, but close to half of such patients are not referred to conventional surgery because of potential comorbidities and high surgical risk.[2](#jah34376-bib-0002){ref-type="ref"} In recent years, several transcatheter mitral valve technologies have emerged as alternatives to surgery for the treatment of MR in patients deemed to be at increased surgical risk. Edge‐to‐edge leaflet repair (MitraClip; Abbott) is the transcatheter mitral valve repair (TMVr) system with the most experience and the only one approved by the US Food and Drug Administration to date. However, a percentage of patients remain suboptimal candidates for this technology, and residual moderate or severe MR after edge‐to‐edge leaflet repair has been reported in ≈10% of patients in real‐world practice.[3](#jah34376-bib-0003){ref-type="ref"}, [4](#jah34376-bib-0004){ref-type="ref"}

Transcatheter mitral valve replacement (TMVR) has emerged as an alternative to TMVr for treating severe MR.[5](#jah34376-bib-0005){ref-type="ref"} A limited number of TMVR systems are under clinical evaluation, and others have started preclinical development programs. The objective of this systematic review is to evaluate the clinical and procedural characteristics and (early and midterm) clinical outcomes associated with TMVR.

Methods {#jah34376-sec-0009}
=======

The data that support the findings of this study are available from the corresponding author on reasonable request.

A comprehensive systematic review of published data describing outcomes from different TMVR systems was performed in agreement with the guidance and the reporting items specified the Preferred Reported Items for Systematic Reviews and Meta‐Analysis (PRISMA) statement.[6](#jah34376-bib-0006){ref-type="ref"} A computerized search was performed to identify all relevant studies from the PubMed and Embase databases. Further data were sought by manual search of secondary sources, including references from primary papers (backward snowballing) and data reported in expert international conferences (Transcatheter Cardiovascular Therapeutics, Transcatheter Valve Therapies, Cardiovascular Research Technologies, EuroPCR, and PCR London Valves). The following keyword terms were used: *TMVR, TMVI* (transcatheter mitral valve implantation)*, transcatheter/percutaneous mitral valve replacement/implantation*. Databases were last accessed January 3, 2019, and studies were included if they were published in English. Transcatheter aortic valve systems used in patients with mitral surgery bioprosthetic or annuloplasty ring dysfunction (valve‐in‐valve and valve‐in‐ring procedures) or patients with severely mitral annular calcification (MAC) were beyond the focus of this systematic review.

The data were extracted using a standardized data abstraction sheet. Clinical characteristics, procedural results, and 30‐day and midterm outcomes were collected as reported by the authors. Two investigators (D.d.V. and A.N.F.‐N.) conducted the literature search selection and data extraction in duplicate. Any discrepancies were resolved by consensus, when needed, with a third investigator (J.R.‐C.). Gathered data included (when available) baseline clinical characteristics and relevant comorbidities, echocardiographic results, procedural details, procedure‐related complications, and follow‐up outcomes. Any TMVR system with at least 1 source (either published or reported in an international congress) describing a clinical experience was included. We excluded studies (1) that included patients using transcatheter aortic valve devices for valve‐in‐valve, valve‐in‐ring, or valve‐in‐MAC procedures; (2) that reported data from preclinical device evaluations; or (3) that reported results only on specialized news websites. When more than 1 reference provided data from the same cohort of patients, only the most recent or the one that provided more detailed data was included.

Statistical Analysis {#jah34376-sec-0010}
--------------------

Continuous variables were expressed as mean±SD. Global cohort values were reported as weighted mean (range) or frequency (percentage). Weighted mean was calculated according to the total number of patients for each device (weight=n). When needed, the method devised by Hozo et al.[7](#jah34376-bib-0007){ref-type="ref"} was used for estimating the standard deviation of the sample. Data analyses were performed using the STATA software (v15.1; StataCorp).

Results {#jah34376-sec-0011}
=======

The searches of PubMed, Embase, and the main international conferences identified 2477, 5752, and 131 records, respectively, yielding 4114 records that were reviewed at the title and abstract level after exclusion of duplicates. Of those, 516 were selected and assessed for eligibility. Finally, 16 publications or conference presentations describing the experience with 11 different dedicated TMVR systems in 308 patients were included.[8](#jah34376-bib-0008){ref-type="ref"}, [9](#jah34376-bib-0009){ref-type="ref"}, [10](#jah34376-bib-0010){ref-type="ref"}, [11](#jah34376-bib-0011){ref-type="ref"}, [12](#jah34376-bib-0012){ref-type="ref"}, [13](#jah34376-bib-0013){ref-type="ref"}, [14](#jah34376-bib-0014){ref-type="ref"}, [15](#jah34376-bib-0015){ref-type="ref"}, [16](#jah34376-bib-0016){ref-type="ref"}, [17](#jah34376-bib-0017){ref-type="ref"}, [18](#jah34376-bib-0018){ref-type="ref"}, [19](#jah34376-bib-0019){ref-type="ref"}, [20](#jah34376-bib-0020){ref-type="ref"}, [21](#jah34376-bib-0021){ref-type="ref"}, [22](#jah34376-bib-0022){ref-type="ref"}, [23](#jah34376-bib-0023){ref-type="ref"} Figure [1](#jah34376-fig-0001){ref-type="fig"} shows the PRISMA flow diagram. The main features of all TMVR systems (Figure [2](#jah34376-fig-0002){ref-type="fig"}) have been described in detail previously and are summarized in Table [1](#jah34376-tbl-0001){ref-type="table"}.[5](#jah34376-bib-0005){ref-type="ref"}, [8](#jah34376-bib-0008){ref-type="ref"}, [24](#jah34376-bib-0024){ref-type="ref"}, [25](#jah34376-bib-0025){ref-type="ref"}, [26](#jah34376-bib-0026){ref-type="ref"}, [27](#jah34376-bib-0027){ref-type="ref"}, [28](#jah34376-bib-0028){ref-type="ref"}, [29](#jah34376-bib-0029){ref-type="ref"}

![Flow diagram based on the Preferred Reported Items for Systematic Reviews and Meta‐Analysis (PRISMA) statement of studies and international conference presentations for evaluating early experience with TMVR. TMVr indicates transcatheter mitral valve repair; TMVR, transcatheter mitral valve replacement.](JAH3-8-e013332-g001){#jah34376-fig-0001}

![Transcatheter mitral valve replacement (TMVR) devices. **A**, AltaValve, provided by 4C Medical. **B**, Fluoroscopic image of the AltaValve. **C** and **D**, Provided by Caisson TMVR‐LivaNova: Caisson TMVR (**C**); fluoroscopy image of the Caisson TMVR (**D**). **E**, CardiAQ Valve, provided by Edwards Lifesciences. **F**, Fluoroscopy image of the CardiAQ Valve. **G** and **H**, Courtesy of Dr Francesco Maisano, Heart Center University Hospital, Zurich, Switzerland: CardioValve (**G**); fluoroscopy image of the CardioValve (**H**). **I** and **J**, Reprinted from Regueiro et al[15](#jah34376-bib-0015){ref-type="ref"} with permission from Elsevier: Fortis (**I**); fluoroscopy image of the Fortis (**J**). **K** and **L**, Courtesy of HighLife Medical: HighLife (**K**); fluoroscopy image of the HighLife (**L**). **M** and **N**, Courtesy of Dr Vinayak Bapat, New York Presbyterian Hospital/Columbia University Medical Center: Intrepid TMVR (**M**); fluoroscopy image of the Intrepid TMVR (**N**). **O**,MValve System. **P**, Fluoroscopy image of the MValve System, courtesy of Dr Maurice Buchbinder, Stanford University/VA Palo Alto Healthcare System, California. **Q** and **R**, Provided by Neovasc Medical Inc: Tiara (**Q**); fluoroscopy image of the Tiara (**R**). **S** and **T**, Courtesy of Dr John Webb, St. Paul\'s Hospital, Vancouver, Canada: Sapien M3 System (**S**); fluoroscopy image of the Sapien M3 System (**T**). **U**, Tendyne. **W**, Fluoroscopy image of the Tendyne.](JAH3-8-e013332-g002){#jah34376-fig-0002}

###### 

Characteristics of Main TMVR Devices

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Device          Manufacturer              Frame                                                       Leaflets             Anchoring Mechanism                                                                          Approach and Delivery System Diameter                   Valve Size (mm)
  --------------- ------------------------- ----------------------------------------------------------- -------------------- -------------------------------------------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------------------------------------------
  AltaValve       4C Medical Technologies   Self‐expanding, nitinol                                     3 bovine leaflets    Spherical frame shape                                                                        Transapical 32‐Fr                                       27

  Caisson TMVR    LivaNova                  Self‐expanding, nitinol                                     3 porcine leaflets   4 subannular anchoring feet\                                                                 Transfemoral--transeptal\                               36A\
                                                                                                                             3 atrial holding features                                                                    31‐Fr                                                   42A\
                                                                                                                                                                                                                                                                                  42B

  CardiAQ Valve   Edwards Lifesciences      Self‐expanding, nitinol                                     3 bovine leaflets    LV anchors that engage the native mitral leaflets and annulus                                Transapical\                                            30
                                                                                                                                                                                                                          Transfemoral--transeptal\                               
                                                                                                                                                                                                                          33‐Fr                                                   

  CardioValve     Cardiovalve                                                                                                                                                                                             Transfemoral‐transeptal\                                3 sizes
                                                                                                                                                                                                                          28‐Fr                                                   

  Fortis          Edwards Lifesciences      Cloth‐covered, self‐expanding, nitinol                      3 bovine leaflets    2 Opposing paddles                                                                           Transapical\                                            29
                                                                                                                                                                                                                          42‐Fr                                                   

  HighLife        HighLife SAS              Self‐expanding, nitinol                                     3 bovine leaflets    Valve in subannular mitral ring; external anchor                                             Transapical (transfemoral artery for loop placement)\   31
                                                                                                                                                                                                                          39‐Fr                                                   

  Intrepid TMVR   Medtronic                 Double stent, self‐expanding, nitinol                       3 bovine leaflets    Radial force and small cleats on outer stent engage leaflets                                 Transapical\                                            27 (with 3 outer stent sizes: 43, 46 and 50 mm)
                                                                                                                                                                                                                          35‐Fr                                                   

  MValve system   MValve Technologies       Dock system to be used with commercially available valves   NA                   External anchor                                                                              Transapical\                                            NA
                                                                                                                                                                                                                          32‐Fr                                                   

  Tiara           Neovasc                   Self‐expanding, nitinol                                     3 bovine leaflets    3 ventricular anchoring tabs (onto the fibrous trigone and posterior shelf of the annulus)   Transapical\                                            35 and 40
                                                                                                                                                                                                                          32‐Fr (35‐mm valve)\                                    
                                                                                                                                                                                                                          36‐Fr (40‐mm valve)                                     

  Sapien M3       Edwards Lifesciences      Balloon‐expandable, cobalt‐chromium frame                   3 bovine leaflets    Nitinol dock system                                                                          Transfemoral\                                           29
                                                                                                                                                                                                                          20‐Fr                                                   

  Tendyne         Abbott                    Double frame, self‐expandable, nitinol                      3 porcine leaflets   Apical tether                                                                                Transapical\                                            Outer (sealing) frame ranges 30--43 mm in the SL dimension and 34--50 in the IC dimension
                                                                                                                                                                                                                          34‐Fr                                                   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IC indicates intercommisural; LV, left ventricular; NA, not available; SL, septal‐to‐lateral; TMVR, transcatheter mitral valve replacement.

Baseline Characteristics {#jah34376-sec-0012}
------------------------

The main baseline clinical characteristics of TMVR recipients are described in Table [2](#jah34376-tbl-0002){ref-type="table"}. The mean age of the patients was 75 years (range: 69--81 years), and 65.9% of patients were men. Most patients (81.5%) were in New York Heart Association (NYHA) class III or IV, and almost half (47.2%) exhibited at least 1 episode of heart failure hospitalization within the year before the TMVR procedure. The mean Society for Thoracic Surgery Predicted Risk of Mortality (STS‐PROM) score was 7.7±0.8%, ranging from 6.14% to 8.6%. Severe comorbidities were frequent, including coronary artery disease (70.3%), prior coronary artery bypass grafting (44.2%), chronic renal insufficiency (60.3%), and atrial fibrillation (55.2%). Mean left ventricular (LV) ejection fraction was 42±4% (range: 30--46%). The indication for TMVR was predominantly secondary (functional) or mixed severe MR (87.1%), and 36 patients (12.9%) were diagnosed with primary MR.

###### 

Baseline Clinical Characteristics

                                            AltaValve (n=1)   Caisson (n=23)   CardiAQ (n=26)   Cardio‐ Valve (n=5)   Fortis (n=13)   HighLife (n=15)   Intrepid (n=50)   MValve System (n=1)   Tiara (n=59)   Sapien M3 (n=15)   Tendyne (n=100)   Global Cohort (N=308)[a](#jah34376-note-0003){ref-type="fn"}
  ----------------------------------------- ----------------- ---------------- ---------------- --------------------- --------------- ----------------- ----------------- --------------------- -------------- ------------------ ----------------- --------------------------------------------------------------
  Age, y                                    77                81               80±8             NA                    71±8            69 (50--79)       NA                75                    74±10          76 ±12             75.4 ±8.1         75.2 (69--81)
  Female                                    0 (0)             13/20 (65)       2/14 (14.3)      NA                    3 (23.1)        3 (20)            21 (42)           NA                    16 (27)        9 (60)             31 (31)           98/287 (34.1)
  STS‐PROM Score (%)                        NA                8.3 ±3.3         6.14             NA                    7.2±3.6         NA                6.4±5.5           NA                    8.6±7.1        8.3±4.3            7.8 ±5.7          7.7 (6.1--8.6)
  Etiology of MR                                                                                                                                                                                                                                    
  Primary                                                     4/20 (20)        6 (23.1)         NA                    0 (0.0)                           8 (16.0)          1 (100)               6/58 (10)      NA                 11 (11)           36/280 (12.9)
  Secondary                                 1 (100)           11/20 (55)       20 (76.9)        NA                    12 (92.3)       11 (73)           36 (72.0)                               37/58 (64)     NA                 89 (89)           217/280 (77.5)
  Mixed MR                                                    5/20 (25)                         NA                    1 (7.7)                           6 (12.0)                                15/58 (26)     NA                                   27/280 (9.6)
  Grade III or IV MR severity               NA                23 (100)         12/12 (100)      NA                    13 (100)        NA                49 (98)           NA                    NA             15 (100)           99 (99)           211/213 (99.1)
  NYHA class                                                                                                                                                                                                                                        
  III--IV                                   1 (100)           16/20 (70)       NA               NA                    13 (100)                          43 (86)           1 (100)               56 (95)        15 (100)           66 (66)           211/259 (81.5)
  LV ejection fraction                      30                45.0±11.5        42.88            NA                    34±9            38 (27--54)       43.4±11.8         NA                    37.2±8         39.8 ±9.4          46.4 ±9.6         42.4 (30--46.4)
  Diabetes mellitus                         NA                6 (25)           0/4 (0)          NA                    5 (38.5)        NA                21 (42.0)         NA                    NA             NA                 38 (38)           70/190 (36.8)
  Hypertension                              NA                22 (95)          NA               NA                    NA              NA                NA                NA                    NA             NA                 80 (80)           102/123 (82.9)
  Atrial fibrillation                       1 (100)           13 (55)          2/4 (50)         NA                    8 (61.5)        NA                29 (58.0)         NA                    33 (56)        5 (33)             NA                91/165 (55.2)
  Coronary artery disease                   1 (100)           16 (70)          NA               NA                    10 (76.9)       NA                34 (68.0)         NA                    NA             7 (46.7)           74 (74)           142/202 (70.3)
  Prior myocardial infarction               NA                7 (30)           3/4 (75)         NA                    NA              NA                22 (44.0)         NA                    NA             NA                 57 (57)           89/177 (50.3)
  Prior coronary artery bypass surgery      1 (100)           NA               10/13 (77)       NA                    7 (53.8)        NA                19 (38.0)         NA                    21 (36)        6 (40)             47 (47)           111/251 (44.2)
  Prior valve intervention/surgery          1 (100)           15 (65)          NA               NA                    NA              5 (33)            5 (10.0)          1 (100)               15 (25)        NA                 0 (0)             42/249 (16.9)
  Chronic renal insufficiency               NA                10 (45)          NA               NA                    NA              NA                29 (58.0)         NA                    45 (76)        5 (33)             60 (60)           149/247 (60.3)
  Chronic obstructive pulmonary disease     NA                8 (35)           2/4 (50)         NA                    5 (38.5)        NA                25 (50.0)         NA                    16 (27)        NA                 39 (39)           95/249 (38.2)
  Prior stroke or TIA                       NA                2 (10)           1/4 (25)         NA                    3 (23.1)        NA                8 (16.0)          NA                    NA             NA                 16 (16)           30/190 (15.8)
  Pulmonary hypertension                    NA                9 (40)           3/7 (43)         NA                    NA              NA                20 (40.0)         NA                    NA             NA                 NA                32/80 (40.0)
  Hospitalization for HF within past year   NA                NA               NA               NA                    9 (69.2)        NA                29 (58.0)         NA                    NA             NA                 39 (39)           77/163 (47.2)

Values are mean±SD or n (%) except as noted. HF indicates heart failure; LV, left ventricular; MR, mitral regurgitation; NA, not available; NYHA, New York Heart Association; STS‐PROM, Society of Thoracic Surgeons Predicted Risk of Mortality; TIA, transient ischemic attack.

Values are weighted mean (range) or n/N (%).

Procedural and 30‐Day Results {#jah34376-sec-0013}
-----------------------------

Procedural details and 30‐day outcomes are shown in Table [3](#jah34376-tbl-0003){ref-type="table"}. The vast majority of procedures were performed under general anesthesia and transesophageal echocardiographic guidance. Most patients (81.5%) underwent TMVR through the transapical approach. The valve was successfully implanted in most patients, with overall reported technical success of 91.7%. Early TMVR‐related complications included valve malposition in 8 of 236 patients (3.4%), device embolization or migration in 2 of 254 patients (0.8%), valve thrombosis in 3 of 179 patients (1.7%), and LV outflow tract obstruction and acute valve dysfunction in 1 patient each (0.4%). These complications led to conversion to open heart surgery in 11 of 272 patients (4.0%). Procedure‐related mortality was reported in 13 of 280 patients (4.6%). Data on residual MR were available for most patients, with only 4 (1.5%) presenting moderate to severe MR after the procedure. Postprocedural mean transmitral gradient was 3.5mm Hg (range: 3.0--5.53 mm Hg). Patients were discharged at a mean of 10 days (range: 6.3--11.1 days) after the procedure. All‐cause 30‐day mortality and rehospitalization rates were 13.6% (range: 0--60%) and 15.8% (12 of 76 patients), respectively.

###### 

Procedural and 30‐Day Clinical Outcomes

                                     AltaValve   Caisson        CardiAQ        CardioValve   Fortis[a](#jah34376-note-0005){ref-type="fn"}   HighLife      Intrepid        MValve System   Tiara          Sapien M3      Tendyne         Global Cohort[b](#jah34376-note-0006){ref-type="fn"}
  ---------------------------------- ----------- -------------- -------------- ------------- ----------------------------------------------- ------------- --------------- --------------- -------------- -------------- --------------- ------------------------------------------------------
  All‐cause 30‐d mortality           0/1 (0.0)   2/11 (18.2)    7/26 (26.9)    3/5 (60.0)    5/13 (38.5)                                     3/15 (20.0)   7/50 (14.0)     1/1 (100)       6/58 (10.3)    0/15 (0.0)     6/100 (6.0)     40/295 (13.6)
  Procedure‐related mortality        0/1 (0.0)   NA             3/26 (11.5)    1/5 (20.0)    4/13 (30.8)                                     2/11 (18.2)   3/50 (6.0)      NA              0/59 (0.0)     0/15 (0.0)     0/100 (0.0)     13/280 (4.6)
  Technical success                  1/1 (100)   18/23 (78.3)   22/26 (84.6)   5/5 (100)     10/13 (76.9)                                    8/11 (72.7)   48/49 (97.9)    1/1 (100)       56/59 (94.9)   13/15 (86.7)   97/100 (97.0)   278/303 (91.7)
  Procedure time, min                NA          177 ±65        NA             43.6±13.1     123±27                                          NA            100 (80--124)   NA              82 (60--155)   189 ±100       136.1±36.3      121.4 (43.6--189)
  Approach                                                                                                                                                                                                                               
  Transfemoral                                   23/23 (100)    14/26 (53.8)   5/5 (100)                                                                                                                  15/15 (100)                    57/308 (18.5)
  Transapical                        1/1 (100)                  12/26 (46.2)                 13/13 (100)                                     15/15 (100)   50/50 (100)     1/1 (100)       59/59 (100)                   100/100 (100)   251/308 (81.5)
  Conversion to open heart surgery   0/1 (0.0)   4/23 (17.4)    NA             NA            2/13 (15.4)                                     2/11 (18.2)   0/50 (0.0)      NA              3/59 (5.1)     0/15 (0.0)     0/100 (0.0)     11/272 (4.0)
  LVOT obstruction                   0/1 (0.0)   0/17 (0.0)     NA             0/5 (0.0)     0/13 (0.0)                                      1/15 (6.6)    0/50 (0.0)      NA              0/58 (0.0)     0/15 (0.0)     0/100 (0.0)     1/274 (0.4)
  Device embolization or migration   0/1 (0.0)   0/17 (0.0)     NA             NA            0/13 (0.0)                                      NA            0/50 (0.0)      NA              2/58 (3.4)     0/15 (0.0)     0/100 (0.0)     2/254 (0.8)
  Malposition                        0/1 (0.0)   NA             1/13 (7.7)     NA            1/13 (7.7)                                      NA            1/50 (2.0)      NA              3/59 (5.1)     NA             2/100 (2.0)     8/236 (3.4)
  Moderate or severe MR              0/1 (0.0)   1/11 (9.1)     0/26 (0.0)     0/5 (0.0)     0/13 (0.0)                                      0/15 (0.0)    0/50 (0.0)      NA              1/37 (2.7)     1/15 (6.6)     1/100 (1.0)     4/273 (1.5)
  Valve dysfunction                  0/1 (0.0)   NA             NA             NA            0/13 (0.0)                                      0/11 (0.0)    0/50 (0.0)      NA              NA             1/15 (6.6)     0/100 (0.0)     1/190 (0.5)
  Device thrombosis                  0/1 (0.0)   NA             NA             NA            1/13 (7.7)                                      1/15 (6.6)    0/50 (0.0)      NA              NA             NA             1/100 (1.0)     3/179 (1.7)
  Stroke                             0/1 (0.0)   0/11 (0.0)     NA             NA            0/13 (0.0)                                      0/15 (0.0)    2/50 (4.0)      NA              2/37 (5.4)     1/15 (6.6)     2/100 (2.0)     7/242 (2.9)
  Bleeding                           0/1 (0.0)   0/11 (0.0)     1/13 (7.7)     1/5 (20.0)    0/13 (0.0)                                      NA            9/50 (18.0)     NA              NA             0/15 (0.0)     20/100 (20.0)   31/208 (14.9)
  Access site complication           0/1 (0.0)   0/11 (0.0)     NA             1/5 (20.0)    NA                                              NA            0/50 (0.0)      NA              4/58 (6.9)     0/15 (0.0)     1/100 (1.0)     6/240 (2.5)
  Acute kidney injury                0/1 (0.0)   NA             NA             NA            2/13 (15.4)                                     NA            5/50 (10.0)     NA              12/37 (32.4)   1/15 (6.6)     8/100 (8.0)     28/216 (13.0)
  Mean transmitral gradient, mm Hg   NA          3.1            NA             4.4           3±1                                             NA            4.1±1.3         NA              NA             5.53±2.2       3.0±1.1         3.5 (3.0--5.53)
  Length of stay, d                  9           NA             NA             NA            10±6                                            NA            NA              NA              NA             6.3 ±3.2       11.1±8.7        10.4 (6.3--11.1)

Values are mean±SD or n/N (%) except as noted. LVOT indicates left ventricular outflow tract; MR, mitral regurgitation; NA, not available.

In late 2015, Edwards Lifesciences stopped the Fortis program. The valve is not currently available.

Values are weighted mean (range) or n/N (%).

Midterm Follow‐Up {#jah34376-sec-0014}
-----------------

Follow‐up (\>30‐day) data were available for 7 of 11 TMVR systems. Mean follow‐up was 10.1±0.3 months, ranging from 3 to 24 months. The main clinical outcomes during the follow‐up period are summarized in Table [4](#jah34376-tbl-0004){ref-type="table"}. The all‐cause mortality rate was 27.6% (71/257 patients), with cardiovascular‐related mortality of 23.3% (38/163 patients). Functional status improved in the majority of patients, with 125 of 146 (85.6%) exhibiting NYHA class I or II at follow‐up. Overall, 26.4% of patients were hospitalized because of acute decompensated heart failure during the follow‐up period, and a stroke event occurred in 8 of 176 patients (4.5%). Echocardiographic data at follow‐up were available for 83 patients, with no cases of moderate to severe MR and a mean transmitral gradient of 3.3±0.3 mm Hg. TMVR‐related complications including device thrombosis, device hemolysis, and endocarditis were reported in 3 of 100 (3.0%), 6 of 150 (4.0%), and 4 of 150 (4.0%) patients, respectively. Reintervention for mitral valve dysfunction was required in 4 of 174 patients (2.3%). There were no cases of device fracture or embolization during the follow‐up period.

###### 

Midterm Clinical Outcomes

                                     Caisson       CardiAQ       Fortis[a](#jah34376-note-0008){ref-type="fn"}   HighLife      Intrepid       Tiara          Tendyne        Global Cohort[b](#jah34376-note-0009){ref-type="fn"}
  ---------------------------------- ------------- ------------- ----------------------------------------------- ------------- -------------- -------------- -------------- ------------------------------------------------------
  Follow‐up, mo                      9.9           NA            24[a](#jah34376-note-0008){ref-type="fn"}       12            7.04±6.7       3              13.7           10.1 (3--24)
  Any mortality                      2/11 (18.2)   9/13 (69.2)   7/13 (53.8)                                     4/15 (26.7)   11/50 (22.0)   12/55 (21.8)   26/100 (26)    71/257 (27.6)
  Cardiovascular mortality           NA            NA            5/13 (38.5)                                     NA            11/50 (22.0)   NA             22/100 (22)    38/163 (23.3)
  NYHA class III--IV                 1/9 (11.1)    NA            1/8 (12.5)                                      NA            9/43 (20.9)    1.9±0.6        10/86 (11.6)   21/146 (14.4)
  Mean transmitral gradient, mm Hg   NA            NA            3±1                                             NA            4.1±1.3        NA             3.0±1.1        3.3 (3--4.1)
  Moderate or severe MR              0/9 (0.0)     0/12 (0.0)    0/8 (0.0)                                       0/12 (0.0)    0/42 (0)       NA             NA             0/83 (0.0)
  Stroke                             2/11 (18.2)   NA            NA                                              0/15 (0.0)    3/50 (6.0)     NA             3/100 (3)      8/176 (4.5)
  Myocardial infarction              0/11 (0.0)    NA            NA                                              0/15 (0.0)    0/50 (0.0)     NA             4/100 (4)      4/176 (2.3)
  HF hospitalization                 1/11 (9.1)    NA            2/13 (15.4)                                     NA            12/50 (24.0)   NA             31/100 (31)    46/174 (26.4)
  Reintervention for mitral valve    0/11 (0.0)    NA            0/13 (0.0)                                      NA            0/50 (0.0)     NA             4/100 (4)      4/174 (2.3)
  Bioprosthetic valve dysfunction    NA            NA            0/13 (0.0)                                      0/15 (0.0)    NA             NA             0/100 (0)      0/128 (0.0)
  Device hemolysis                   NA            NA            NA                                              NA            NA             NA             3/100 (3)      3/100 (3.0)
  Device embolization                NA            NA            0/13 (0.0)                                      NA            0/50 (0.0)     NA             0/100 (0)      0/163 (0.0)
  Device thrombosis                  NA            NA            NA                                              NA            0/50 (0.0)     NA             6/100 (6)      6/150 (4.0)
  Fracture                           NA            NA            0/13 (0.0)                                      NA            NA             NA             0/100 (0)      0/113 (0.0)
  Endocarditis                       NA            NA            NA                                              NA            2/50 (4.0)     NA             2/100 (2)      4/150 (2.7)

Values are mean±SD or n/N (%) except as noted. HF indicates heart failure; MR, mitral regurgitation; NA, not available; NYHA, New York Heart Association.

In late 2015, Edwards Lifesciences stopped the Fortis program. The valve is not currently available.

Values are weighted mean (range) or n/N (%).

Discussion {#jah34376-sec-0015}
==========

The main findings of this systematic review on the initial TMVR experience in patients with severe MR can be summarized as follows. First, the data support the feasibility of TMVR, with a high rate of successful valve implantation. Second, TMVR was associated with excellent hemodynamic results, with a very low rate of significant residual MR and low transvalvular mitral gradients after the procedure. Third, the rates of periprocedural complications and early mortality were relatively high. Fourth, most patients improved their functional class, but the mortality rate remained high (28%) after a mean follow‐up of about 1 year.

Patient Selection Considerations {#jah34376-sec-0016}
--------------------------------

This review showed that patients selected for TMVR were elderly and exhibited a high comorbidity burden, leading to high to prohibitive surgical risk. In addition, most patients had secondary MR, with reduced LV ejection fraction. Appropriate patient selection for TMVR may be challenging and requires a global assessment including patient comorbidities, mechanisms of MR, and structural/anatomical features. Unfortunately, limited data were provided on inclusion and exclusion criteria and screen failure rates in most TMVR series. Although these details were formally reported in only 2 registries, the global rate of screen failure was presumably high. In the Tendyne Global Feasibility Study, only 100 of 332 patients screened were finally included (screen failure ≈70%).[23](#jah34376-bib-0023){ref-type="ref"} Similarly, in the Global Pilot Study with the Intrepid TMVR system, only 50 of 166 patients screened were selected. The most common exclusion criteria were severe LV dysfunction, large annulus dimensions, high risk of LV outflow tract obstruction, severe mitral annular or leaflet calcification, previous mitral or aortic valve surgery, intracardiac thrombus, severe pulmonary hypertension, severe tricuspid valve regurgitation, and severe right ventricular dysfunction. Moreover, patient selection was limited by valve size availability in some cases.

The mitral valve apparatus is a complex dynamic structure and multiple important anatomical aspects should be considered. Unlike transcatheter aortic valve replacement, TMVR must address challenges such as (1) noncircular saddle‐shape dynamic annulus of large dimensions, (2) lack of calcified or rigid mitral annulus, (3) irregular leaflets geometry, (4) proximity of LV outflow tract, and (5) the presence of the subvalvular apparatus. Thus, the use of imaging techniques like 3‐dimensional computed tomography is key for evaluating patient eligibility, and anatomical issues remain the most important factor determining TMVR feasibility.[30](#jah34376-bib-0030){ref-type="ref"}

Procedural Aspects and Early Outcomes {#jah34376-sec-0017}
-------------------------------------

The vast majority of procedures (\>80%) were performed through a transapical approach, with only 4 devices implanted through a transfemoral--transeptal approach Sapien M3 (Edwards Lifesciences, Irvine, CA, USA), Caisson (LivaNova PLC, London, UK), CardiAQ (Edwards Lifesciences, Irvine, CA, USA) and CardioValve (Cardiovalve Ltd., Or Yehuda, Israel). This choice is related to the large size of the valve‐delivery catheters along with the location of the mitral valve, which makes the appropriate alignment of the transcatheter valve more difficult when using the antegrade transeptal approach. Although this study represented the initial experience with different TMVR platforms, technical success was high, and successful valve implantation was achieved in up to 92% of cases (range: 73--100%). In addition, significant LV outflow tract obstruction was reported in only 1 case, probably reflecting the appropriateness of preprocedural imaging workup along with conservative eligibility criteria. However, conversion to open heart surgery was required in 4% of patients. The causes were chordal entanglement (2 cases), valve malposition (4 cases), and the presence of multiple papillary muscles, a septal bulge, and a thickened LV posterior wall impeding the proper placement of a wire after apical puncture (1 case). While these complications may be part of the learning curve process, it highlights the importance of heart teams and specialized centers with high surgical experience dedicated to these procedures.

Importantly, the results regarding valve performance showed a very low rate of significant residual MR (moderate or severe: 1.5%) and low transvalvular gradients (mean: \<4 mm Hg) following the procedure. These results appear to be similar to those associated with surgical mitral valve repair and replacement[3](#jah34376-bib-0003){ref-type="ref"} and superior to those reported in transcatheter TMVr series, including the most recent studies with the MitraClip device.[31](#jah34376-bib-0031){ref-type="ref"}, [32](#jah34376-bib-0032){ref-type="ref"}, [33](#jah34376-bib-0033){ref-type="ref"}, [34](#jah34376-bib-0034){ref-type="ref"}, [35](#jah34376-bib-0035){ref-type="ref"} Despite the good results regarding procedural success and valve performance, the 30‐day mortality rate after TMVR was as high as 13.6% (varying from 0% to 60%), which exceeded the estimated surgical risk (mean STS‐PROM of the study population: ≈8%) and was much higher than that reported in TMVr series including patients with a similar risk profile.[31](#jah34376-bib-0031){ref-type="ref"}, [36](#jah34376-bib-0036){ref-type="ref"} The causes of such high periprocedural mortality are probably multifactorial. First, in addition to the significant comorbidity burden, the fact that most patients had secondary MR as the underlying disease may have contributed.[37](#jah34376-bib-0037){ref-type="ref"}, [38](#jah34376-bib-0038){ref-type="ref"} Second, the rate of periprocedural complications like major or life‐threatening bleeding or acute kidney injury---both associated with poorer outcomes---was high (\>10%). This may be partially related to the use of the transapical approach in most patients, which has also been associated per se with a negative clinical impact, particularly in elderly and frail patients.[39](#jah34376-bib-0039){ref-type="ref"}, [40](#jah34376-bib-0040){ref-type="ref"} Third, the myocardial injury secondary to the transapical approach may be particularly deleterious in patients with already reduced ventricular function.[41](#jah34376-bib-0041){ref-type="ref"} Similar to the transcatheter aortic valve replacement field, a progressive transition toward increasing use of transfemoral systems will likely occur in the near future and may translate into improved outcomes. Finally, the learning curve process probably contributed to the high mortality rate observed in this initial TMVR experience.

Midterm Outcomes {#jah34376-sec-0018}
----------------

Although the results were highly heterogeneous among different TMVR systems, the mean mortality rate was as high as 28% after a mean follow‐up close to 1 year. This rate is similar to that reported by the STS/ACC TVT Registry (Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy) including 2952 patients (mean STS‐PROM: ≈6%) with secondary MR treated with the MitraClip system.[31](#jah34376-bib-0031){ref-type="ref"} Although the high noncardiac comorbidity burden of TMVR recipients may have contributed, it has to be noted that about half of the deaths were related to cardiovascular causes. In addition, a significant proportion of patients were hospitalized for heart failure decompensation within the months following the procedure. Importantly, no deaths specifically related to transcatheter valve dysfunction were reported. Two recent trials evaluating the efficacy of TMVr with the MitraClip system for treating secondary MR provided contradictory results,[34](#jah34376-bib-0034){ref-type="ref"}, [35](#jah34376-bib-0035){ref-type="ref"} highlighting the importance of adequate patient selection to avoid treatment futility in this population. Future studies are needed to determine which patients may benefit the most from TMVR.

Although the follow‐up duration was limited, no signs of early valve degeneration were detected following TMVR (up to 1‐year follow‐up). Future studies with longer follow‐up should provide extended valve durability data. However, device thrombosis was reported in 3% of patients, highlighting the importance of appropriate antithrombotic treatment following these procedures. Anticoagulation therapy for a minimum of 3 months was recommended in most TMVR studies, probably mimicking the recommendations from current guidelines regarding conventional surgical mitral valve replacement. Future studies will need to evaluate the optimal antithrombotic strategy in these patients.

TMVR Versus TMVr {#jah34376-sec-0019}
----------------

Several TMVr techniques, based on surgical repair techniques, are being simultaneously developed as a minimally invasive alternative to patients who are not candidates for surgery. MITRA‐FR (Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation) showed no benefit of MitraClip in patients with severe secondary MR on optimized medical treatment.[35](#jah34376-bib-0035){ref-type="ref"} However, the COAPT (Clinical Outcomes Assessment of the MitraClip Percutaneous Therapy) trial demonstrated significantly lower all‐cause mortality and rehospitalization for heart failure in patients who underwent the MitraClip procedure.[34](#jah34376-bib-0034){ref-type="ref"} Main patient baseline characteristic and results comparing the TMVR population with the COAPT device group are summarized in Table [5](#jah34376-tbl-0005){ref-type="table"}.

###### 

Baseline Characteristics, Procedural and 30‐Day Results, and Midterm Outcomes Comparing the TMVR Cohort With the COAPT Device Group

                                                                     TMVR (N=308)     COAPT Device Group (N=302)
  ------------------------------------------------------------------ ---------------- -----------------------------------------------------
  Characteristics of the patients at baseline                                         
  Age, y                                                             75.2±3.5         72.2±11.2
  STS‐PROM score, %                                                  7.7±0.75         7.8±5.5
  Secondary MR                                                       217/280 (77.5)   302/302 (100)
  Grade III or IV MR severity                                        211/213 (99.1)   302/302 (100)
  Left ventricular ejection fraction                                 42.4±4.7         31.3±9.3
  Hypertension                                                       102/123 (82.9)   243/302 (80.5)
  Diabetes mellitus                                                  70/190 (36.8)    106/302 (35.1)
  Prior myocardial infarction                                        89/177 (50.3)    156/302 (51.7)
  Prior coronary artery bypass surgery                               111/251 (44.2)   121/302 (40.1)
  Chronic obstructive pulmonary disease                              95/249 (38.2)    71/302 (23.5)
  Hospitalization for HF within past year                            77/163 (47.2)    176/302 (58.3)
  Procedural and 30‐d clinical outcomes                                               
  Procedure time, min                                                121.4±41.9       162.9±118.1
  All‐cause 30‐d mortality                                           40/295 (13.6)    7/302 (2.3)
  Stroke                                                             7/242 (2.9)      2/302 (0.7)
  Moderate or severe MR                                              4/273 (1.5)      20/273 (7.3)
  Unplanned mitral valve surgery                                     11/272 (4.0)     0/302 (0.0)
  Midterm clinical outcomes[a](#jah34376-note-0011){ref-type="fn"}                    
  Any mortality during follow‐up                                     71/257 (27.6)    57/302 (18.9)
  NYHA class III--IV                                                 21/146 (14.4)    48/237 (20.3)
  Moderate or severe MR                                              0/83 (0.0)       11/210 (5.2)
  HF hospitalization                                                 46/174 (26.4)    92/302 (35.7)
  Unplanned mitral valve reintervention                              4/174 (2.3)      10/302 (3.3)[b](#jah34376-note-0012){ref-type="fn"}
  Device embolization or migration                                   2/254 (0.8)      1/293 (0.3)
  Endocarditis                                                       4/150 (2.7)      0/293 (0.0)

Values are mean±SD or n/N (%). COAPT indicates Clinical Outcomes Assessment of the MitraClip Percutaneous Therapy; HF, heart failure; MR, mitral regurgitation; NYHA, New York Heart Association; STS‐PROM, Society of Thoracic Surgeons Predicted Risk of Mortality; TMVR, transcatheter mitral valve replacement.

Midterm follow‐up for TMVR cohort and COAPT device group were 10.1 and 12 mo, respectively.

Unplanned mitral valve intervention within 24 mo.

Although both techniques have shown promising results, they have some potential theoretical advantages and limitations. TMVr may be technically more challenging, and mitral anatomy is not suitable in all patients. In addition, hemodynamic results with TMVr devices are less predictable, and the rates of at least moderate residual MR are ≈10%.[3](#jah34376-bib-0003){ref-type="ref"}, [4](#jah34376-bib-0004){ref-type="ref"} Safety and procedure‐related complications seem to favor TMVr, probably because of the widely used transfemoral approach, lower profile catheters, and consistent hemodynamic stability during the procedure. Moreover, some concerns have been raised about TMVR platforms. It is well known in the surgical field that in patients \<65 years, bioprosthetic valves degenerate earlier, driving increased reoperation rates and shorter long‐term survival.[42](#jah34376-bib-0042){ref-type="ref"} However, to date, evidence regarding efficacy and long‐term durability with TMVR devices remain unclear. Furthermore, antithrombotic therapy in TMVR patients has yet to be formally established, and evidence is limited regarding the risk of valve thrombosis. Most platforms recommended a minimal anticoagulation treatment duration of 3 months postoperatively, usually based on current guidelines for surgical bioprosthetic valves. Further data are needed to determine the best antithrombotic strategy in this scenario. Consequently, both TMVR and TMVr systems should be considered as complementary treatments in patients with high surgical risk and severe MR.

Study Limitations {#jah34376-sec-0020}
-----------------

This study has the limitations inherent to a systematic review that collects only information described in the publications or reported in international conferences; thus, relevant information might be omitted in the review that could shed some more light on this topic. In addition, this systematic review analyzed a limited series of patients for whom, in some cases, only collective data were available. Indeed, incomplete individual data regarding some patient baseline characteristics, procedure‐related aspects, and follow‐up may have prevented complete and accurate clinical evaluation. Finally, the reported patients might have had better outcomes than those who were not published (ie, selection bias).

In conclusion, TMVR has emerged as a less invasive alternative to conventional surgery for treatment of severe MR in patients with high or prohibitive surgical risk. The early experience with TMVR showed a high rate of technically successful valve implantations and excellent hemodynamic results with a low rate of residual MR. However, despite the heterogeneity of the results, procedure‐related complications and midterm mortality remained high. Improvement of patient selection, further iterations of TMVR systems, and a gradual increase in use of the transfemoral--transeptal approach might be necessary before the widespread adoption of this technology as an alternative to conventional surgery. The confirmation of TMVR as an option complementary to TMVr would drastically increase therapeutic options for patients with severe MR and increased surgical risk.
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